

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Lupin Pharma Canada Limited and Mylan Pharmaceuticals ULC that the shortages for Jencycla 0.35 mg (28 Day) Tablet (DIN 02441306) and Movisse 0.35 mg (28 Day) Tablet (DIN 02410303) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 13, 2020**.

NORETHINDRONE

0.35 MG TABLET

00002441306	JENCYCLA (28 DAY)	LPC	\$ 0.3925
00002410303	MOVISSE (28 DAY)	MYP	\$ 0.3925
00000037605	MICRONOR (28 DAY)	JAI	\$ 0.9536

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Maxidex 0.1% Ophthalmic Suspension (DIN 00042560), manufactured by Novartis Pharmaceuticals Canada Inc., Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865), manufactured by Pharma Stulln Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Novartis Pharmaceuticals Canada Inc. has advised Alberta Blue Cross that the shortage of Maxidex 0.1% Ophthalmic Suspension (DIN 00042560) has been resolved.

As a result, Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865) will no longer be considered a temporary benefit for the *ADBL* after **April 15, 2020**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php